X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
brcaness (129) 129
index medicus (83) 83
humans (81) 81
oncology (77) 77
female (63) 63
breast cancer (52) 52
dna repair (41) 41
cancer (40) 40
homologous recombination (38) 38
mutation (37) 37
chemotherapy (36) 36
brca1 (35) 35
poly polymerase (35) 35
brca1 protein - genetics (32) 32
parp inhibitors (32) 32
tumors (32) 32
middle aged (28) 28
ovarian cancer (27) 27
adult (25) 25
brca2 protein - genetics (24) 24
aged (23) 23
dna damage (23) 23
survival (23) 23
genetic aspects (21) 21
synthetic lethality (20) 20
breast neoplasms - genetics (19) 19
parp inhibitor (19) 19
repair (19) 19
deoxyribonucleic acid--dna (18) 18
brca2 (17) 17
gene expression (17) 17
genes, brca1 (17) 17
ovarian neoplasms - genetics (17) 17
prognosis (17) 17
analysis (16) 16
animals (16) 16
brca1 protein (16) 16
breast neoplasms - pathology (16) 16
genes, brca2 (16) 16
triple negative breast neoplasms - genetics (16) 16
antineoplastic agents - therapeutic use (15) 15
brca1 protein - metabolism (15) 15
cell line, tumor (15) 15
expression (15) 15
resistance (15) 15
biomarkers (14) 14
breast-cancer (14) 14
ovarian neoplasms - drug therapy (14) 14
ovarian-cancer (14) 14
poly polymerase inhibitors (14) 14
cell biology (13) 13
endocrine system diseases (13) 13
homologous recombination deficiency (13) 13
research (13) 13
sensitivity (13) 13
skin and connective tissue diseases (13) 13
triple negative breast neoplasms - drug therapy (13) 13
antineoplastic agents - pharmacology (12) 12
care and treatment (12) 12
cisplatin (12) 12
dna methylation (12) 12
dna-damage (12) 12
genomic instability (12) 12
medicine & public health (12) 12
therapy (12) 12
treatment outcome (12) 12
triple-negative breast cancer (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
dna-damage response (11) 11
genes (11) 11
neoadjuvant chemotherapy (11) 11
ovarian neoplasms - pathology (11) 11
poly polymerase inhibitors - pharmacology (11) 11
proteins (11) 11
brca2 mutations (10) 10
breast (10) 10
cancer therapies (10) 10
carcinoma (10) 10
clinical trials (10) 10
dna-repair (10) 10
gene mutations (10) 10
medicine (10) 10
pathology (10) 10
sporadic breast (10) 10
triple negative breast neoplasms - pathology (10) 10
article (9) 9
biomarkers, tumor - genetics (9) 9
brca mutations (9) 9
cancer research (9) 9
carboplatin (9) 9
cells (9) 9
development and progression (9) 9
gene expression regulation, neoplastic (9) 9
mutations (9) 9
olaparib (9) 9
poly polymerase inhibitors - therapeutic use (9) 9
somatic mutations (9) 9
brca (8) 8
breast neoplasms - drug therapy (8) 8
gene-expression (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Cancer, ISSN 1471-2407, 01/2019, Volume 19, Issue 1, pp. 108 - 12
Journal Article
by Lin, JZ and Shi, JP and Guo, HL and Yang, X and Jiang, Y and Long, JY and Bai, Y and Wang, DX and Yang, XB and Wan, XS and Zhang, L and Pan, J and Hu, K and Guan, M and Huo, L and Sang, XT and Wang, K and Zhao, HT
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 08/2019, Volume 25, Issue 15, pp. 4701 - 4711
Purpose: Alterations in DNA damage repair (DDR) genes produce therapeutic biomarkers. However, the characteristics and significance of DDR alterations remain... 
SURVIVAL | OLAPARIB | HEPATOCELLULAR-CARCINOMA | INTRAHEPATIC CHOLANGIOCARCINOMA | ONCOLOGY | IMMUNOTHERAPY | BLOCKADE | BRCANESS
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 12/2019, Volume 37, Issue 36, pp. 3484 - 3484
PURPOSE To independently validate two biomarkers, a 44-gene DNA damage immune response (DDIR) signature and stromal tumor-infiltrating lymphocytes (sTILs), as... 
TUMOR-INFILTRATING LYMPHOCYTES | SURVIVAL | METASTASIS | ONCOLOGY | RECOMMENDATIONS | ANTHRACYCLINE | DOXORUBICIN | BRCANESS | CLINICAL-PRACTICE | CHEMOTHERAPY
Journal Article
Oncotarget, ISSN 1949-2553, 03/2019, Volume 10, Issue 25, p. 2421
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 04/2018, Volume 24, Issue 8, pp. 1917 - 1931
Purpose: The standard treatment for organ-confined prostate cancer is surgery or radiation, and locally advanced prostate cancer is typically treated with... 
PATHWAYS | RECOMBINATION | ACTIVATOR | REPLICATION | ONCOLOGY | COMET ASSAY | HOMOLOGY-DIRECTED REPAIR | TRANSCRIPTION-5 | PROMOTER | BRCANESS | SIGNAL TRANSDUCER
Journal Article
International Journal of Cancer, ISSN 0020-7136, 10/2017, Volume 141, Issue 7, pp. 1286 - 1294
Targeting deficient mechanisms of cellular DNA repair still represents the basis for the treatment of the majority of solid tumors, and increased DNA repair... 
“BRCAness,” chemotherapy | radiotherapy | RAD51 | prognosis | SURVIVAL | PROTEIN | "BRCAness" | BRCA1 | chemotherapy | BREAST-CANCER | DAMAGE RESPONSE | EX-VIVO ASSAY | ONCOLOGY | PROGNOSTIC MARKER | HOMOLOGOUS RECOMBINATION | EXPRESSION | PREDICTIVE FACTOR | Neoplasms - metabolism | Rad51 Recombinase - metabolism | Cell Proliferation - genetics | Rad51 Recombinase - genetics | Recombinational DNA Repair - genetics | Humans | Radiation Tolerance - genetics | Male | DNA Repair - genetics | DNA, Neoplasm - drug effects | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Neoplasms - drug therapy | Polymorphism, Genetic | Drug Resistance, Neoplasm - genetics | Neoplasms - genetics | Biomarkers, Tumor - metabolism | Genes, BRCA2 | Female | Neoplasms - radiotherapy | Biomarkers, Tumor - genetics | Genes, BRCA1 | DNA, Neoplasm - radiation effects | Precision Medicine | Medical research | Chemotherapy | DNA | Medicine, Experimental | DNA repair | Sugars | Cancer | Monosaccharides | Drugs | Genetic variability | DNA damage | Homologous recombination | Medical services | Clinical trials | Cytotoxicity | Homology | Radioresistance | ADP | Proteins | Rad51 protein | Ribose | Damage | Repair | Deoxyribonucleic acid--DNA | Poly(ADP-ribose) polymerase | Radiation therapy | Gene expression | Polymerase | Biomarkers | Protein expression | Immunoreactivity | Solid tumors | Tumors
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 03/2014, Volume 74, Issue 6, pp. 1651 - 1660
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 11/2017, Volume 104, Issue 11, pp. 988 - 998
The transmission of an intact and stable genetic code at each cell division relies on different DNA repair systems. Germline mutations of some of these genes... 
Homologous recombination | PARP inhibitors | Synthetic lethality | BRCAness | DNA repair
Journal Article
BBA - Reviews on Cancer, ISSN 0304-419X, 08/2014, Volume 1846, Issue 1, pp. 201 - 215
Journal Article
Expert Opinion on Therapeutic Targets, ISSN 1472-8222, 09/2019, Volume 23, Issue 9, pp. 773 - 785
Introduction: The implementation of poly-ADP-ribose polymerase (PARP) inhibitors for therapy has created potential treatments for a wide spectrum of... 
prostate cancer | DNA damage response | BRCA mutations | ovarian cancer | PARP inhibitors | breast cancer | BRCAness | PARP enzymes
Journal Article
Cancer Cell, ISSN 1535-6108, 11/2019, Volume 36, Issue 5, pp. 545 - 558.e7
Epigenetic regulation enables tumors to respond to changing environments during tumor progression and metastases and facilitates treatment resistance.... 
triple-negative breast cancer | PARP inhibitor | CDK12 | cisplatin | CDK13 | BRCAness | intronic polyadenylation | TRANSFORMATION | POLY(ADP-RIBOSE) POLYMERASE | MAINTENANCE | ONCOLOGY | PHOSPHORYLATION | DNA-DAMAGE | KINASE | DISEASE | TRANSCRIPTION REGULATION | EXPRESSION | CELL BIOLOGY
Journal Article